What is William Blair’s Forecast for ELAN FY2025 Earnings?

Elanco Animal Health Incorporated (NYSE:ELAN) – Investment analysts at William Blair increased their FY2025 earnings estimates for shares of Elanco Animal Health in a research note issued to investors on Wednesday, November 5th. William Blair analyst B. Vazquez now anticipates that the company will post earnings per share of $0.93 for the year, up from their previous forecast of $0.91. The consensus estimate for Elanco Animal Health’s current full-year earnings is $0.91 per share. William Blair also issued estimates for Elanco Animal Health’s Q1 2026 earnings at $0.36 EPS, Q3 2026 earnings at $0.19 EPS, Q4 2026 earnings at $0.17 EPS, Q1 2027 earnings at $0.40 EPS, Q2 2027 earnings at $0.32 EPS and FY2027 earnings at $1.11 EPS.

Elanco Animal Health (NYSE:ELAN) last posted its earnings results on Wednesday, November 5th. The company reported $0.19 earnings per share for the quarter, topping the consensus estimate of $0.13 by $0.06. Elanco Animal Health had a net margin of 0.78% and a return on equity of 7.51%. The firm had revenue of $1.14 billion during the quarter, compared to the consensus estimate of $1.09 billion. During the same quarter last year, the company earned $0.13 earnings per share. The company’s revenue was up 10.4% on a year-over-year basis. Elanco Animal Health has set its FY 2025 guidance at 0.910-0.940 EPS. Q4 2025 guidance at 0.090-0.120 EPS.

Other equities research analysts also recently issued research reports about the company. Wall Street Zen downgraded Elanco Animal Health from a “strong-buy” rating to a “buy” rating in a research report on Sunday, November 2nd. Leerink Partnrs raised Elanco Animal Health from a “hold” rating to a “strong-buy” rating in a report on Thursday, July 17th. Stifel Nicolaus boosted their price objective on shares of Elanco Animal Health from $18.00 to $23.00 and gave the company a “buy” rating in a research note on Wednesday, September 24th. UBS Group boosted their price target on shares of Elanco Animal Health from $25.00 to $27.00 and gave the company a “buy” rating in a research report on Thursday. Finally, Piper Sandler lifted their price objective on Elanco Animal Health from $12.00 to $18.00 and gave the company a “neutral” rating in a research note on Monday, August 11th. Two investment analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $20.29.

Elanco Animal Health Stock Down 0.6%

ELAN opened at $21.48 on Friday. Elanco Animal Health has a 12 month low of $8.02 and a 12 month high of $22.98. The company has a market cap of $10.67 billion, a PE ratio of 358.06, a price-to-earnings-growth ratio of 3.30 and a beta of 1.71. The company has a current ratio of 2.60, a quick ratio of 1.40 and a debt-to-equity ratio of 0.61. The company has a 50 day moving average of $20.11 and a 200 day moving average of $16.07.

Hedge Funds Weigh In On Elanco Animal Health

Institutional investors have recently modified their holdings of the company. PNC Financial Services Group Inc. lifted its stake in Elanco Animal Health by 68.8% in the third quarter. PNC Financial Services Group Inc. now owns 22,921 shares of the company’s stock worth $462,000 after purchasing an additional 9,340 shares during the last quarter. DDD Partners LLC increased its holdings in shares of Elanco Animal Health by 6.6% in the third quarter. DDD Partners LLC now owns 1,753,369 shares of the company’s stock worth $35,313,000 after buying an additional 108,941 shares during the period. Caprock Group LLC purchased a new position in shares of Elanco Animal Health in the third quarter worth about $358,000. Rhumbline Advisers lifted its stake in shares of Elanco Animal Health by 190.5% in the 3rd quarter. Rhumbline Advisers now owns 1,319,770 shares of the company’s stock valued at $26,580,000 after acquiring an additional 865,420 shares during the last quarter. Finally, Applied Finance Capital Management LLC purchased a new stake in Elanco Animal Health during the 3rd quarter valued at about $207,000. 97.48% of the stock is currently owned by institutional investors.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.